Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with mild Alzheimer's disease (ELAD Study)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer\'s dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.
Epistemonikos ID: 1c9a48273215b7c715ead5decdce4fe1ad7ab655
First added on: May 11, 2024